Publications by authors named "Jonas Wallvik"

Claim this Profile
D
Direct oral anticoagulants: patient reported adherence and minor bleedings.
Amina Hayat, Anders Själander, Jonas Wallvik

J Thromb Thrombolysis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors.
Dorina Ujvari, Alena Malyukova, Ana Zovko, Elham Yektaei-Karin, Harsha S Madapura, Jonas Wallvik

Oncoimmunology· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.
Alena Malyukova, Dorina Ujvari, Elham Yektaei-Karin, Ana Zovko, Harsha S Madapura, Jonas Wallvik

Cell Death Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
Ana Zovko, Elham Yektaei-Karin, Daniel Salamon, Anders Nilsson, Jonas Wallvik

Oncol Rep· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia.
Elham Yektaei-Karin, Ana Zovko, Anders Nilsson, Barbro Näsman-Glaser, Lena Kanter, Jonas Wallvik

Leuk Lymphoma· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Niklas Gunnarsson, Leif Stenke, Martin Höglund, Fredrik Sandin, Magnus Björkholm, Jonas Wallvik

Br J Haematol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Stephen P Mulligan, Karin Karlsson, Mats Strömberg, Viggo Jønsson, Devinder Gill, Jonas Wallvik

Leuk Lymphoma· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
Herman Nilsson-Ehle, Gunnar Birgegård, Jan Samuelsson, Petar Antunovic, Jan Astermark, Jonas Wallvik

Eur J Haematol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Michael Grövdal, Mohsen Karimi, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jonas Wallvik

Br J Haematol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Jonas Wallvik

Clin Cancer Res· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics.
Jonas Wallvik, Anders Själander, Lars Johansson, Orjan Bjuhr, Jan-Håkan Jansson

Scand J Prim Health Care· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
Karin Karlsson, Mats Strömberg, Jan Liliemark, André Delannoy, S A N Johnson, Jonas Wallvik

Br J Haematol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Jonas Wallvik, Leif Stenke, Per Bernell, Gunnar Nordahl, Erik Hippe

Eur J Haematol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis